A neoadjuvant preparation of patients with esophageal cancer
Neoral, C.; Král, V.; Aujeský, R.; Kohoutek, M.; Bohanes, T.; Grosmanová, T.
Acta Universitatis Palackianae Olomucensis Facultatis Medicae 143: 97-98
2000
ISSN/ISBN: 0301-2514 PMID: 11144146 Document Number: 6062
Document emailed within 1 workday
Related Documents
Fu, J.; Tan, Z. 2018: Is esophagectomy necessary for esophageal cancer patients with complete response after neoadjuvant chemoradiotherapy Zhonghua Wei Chang Wai Ke Za Zhi 21(9): 983-986Ando, N.; Ozawa, S.; Kitagawa, Y.; Takeuchi, H.; Kitajima, M. 1997: Salvage surgery for the T4 esophageal cancer following downstaging by neoadjuvant chemoradiotherapy Nihon Geka Gakkai Zasshi 98(9): 767-772
Yabusaki, H.; Nashimoto, A.; Tanaka, O. 2002: A complete response after neoadjuvant chemotherapy for advanced gastric cancer with esophageal invasion Gan to Kagaku Ryoho. Cancer and ChemoTherapy 29(1): 119-123
Hanna, A.; Birla, R.; Iosif, C.; Boeriu, M.; Tomsa, R.; Puscasu, A.; Constantinoiu, S. 2015: Evaluation of Neoadjuvant Radiochemotherapy Response (RCT) in Squamous Esophageal Cancer (ESC) and Implications in Therapeutic Conduct Chirurgia 110(3): 214-223
Kimura, Y.; Shiraishi, O.; Kawakami, H.; Ueda, H.; Okuno, T.; Hiraki, Y.; Kato, H.; Iwama, M.; Yasuda, A.; Shinkai, M.; Chikugo, T.; Imano, M.; Imamoto, H.; Nakagawa, K.; Yasuda, T. 2018: A Case of Advanced Esophageal Cancer Successfully Treated with Neoadjuvant Chemotherapy Containing 5-FU, Docetaxel. and Nedaplatin Combination Therapy Gan to Kagaku Ryoho. Cancer and ChemoTherapy 45(13): 1812-1814
Yasuda, T.; Kabuto, T.; Ishiguro, S.; Nakano, H.; Nakamori, S.; Ohigashi, H.; Hiratsuka, M.; Kameyama, M.; Sasaki, Y.; Ishikawa, O. 1995: Preoperative neoadjuvant chemotherapy with a combination of 5-fluorouracil, adriamycin and cisplatin (FAP) for advanced esophageal cancer invading trachea or main bronchus Gan to Kagaku Ryoho. Cancer and ChemoTherapy 22(11): 1538-1541
Koide, N.; Komatsu, D.; Hiraga, R.; Kitazawa, M.; Suzuki, A.; Miyagawa, S. 2010: Esophageal cancer associated with other primary cancers--historical comparison of clinicopathologic features in 359 esophageal cancer patients Hepato-Gastroenterology 57(99-100): 513-518
Yang, H.; Yao, J.; Wen, H.; Yu, L.; Liu, W.; Liang, H.; Han, S. 2015: Clinical evaluations of neoadjuvant chemotherapy with DN and FP regimens for patients with middle or lower thoracic locally advanced esophageal squamous cell carcinoma Zhonghua Yi Xue Za Zhi 95(19): 1530-1533
Gasowska-Bodnar, A.; Bodnar, L.; Wcisło, G.B.; Jerzak, M.łg.M.; Szczylik, C.; Baranowski, W.ło. 2008: CA 125 regression after two cycles of neoadjuvant chemotherapy as prognostic factor in patients with advanced ovarian cancer and primary peritoneal serous cancer who underwent interval surgical cytoreduction Ginekologia Polska 79(2): 108-114
Pasetto, L.Maria.; Friso, M.Luisa.; Pucciarelli, S.; Basso, U.; Falci, C.; Bortolami, A.; Toppan, P.; Agostini, M.; Rugge, M.; Serpentini, S.; Nitti, D.; Monfardini, S. 2006: Rectal cancer neoadjuvant treatment in elderly patients Anticancer Research 26(5b): 3913-3923
Zhang, B.; Zhang, Q. 2007: Neoadjuvant systemic chemotherapy for patients with operable breast cancer Zhonghua Zhong Liu Za Zhi 29(3): 161-165
Stamatovic, L.; Susnjar, S.; Gavrilovic, D.; Minic, I.; Ursulovic, T.; Dzodic, R. 2018: The influence of breast cancer subtypes on the response to anthracycline neoadjuvant chemotherapy in locally advanced breast cancer patients Journal of Buon: Official Journal of the Balkan Union of Oncology 23(5): 1273-1280
Mamounas, T.P. 2013: Predicting locoregional recurrence after neoadjuvant chemotherapy in patients with breast cancer Clinical Advances in Hematology and Oncology: H&o 11(3): 175-177
White, J. 2013: Management of the axilla in breast cancer patients undergoing neoadjuvant therapy Clinical Advances in Hematology and Oncology: H&o 11(12): 796-798
Franceschini, G.; Di Leone, A.; Natale, M.; Sanchez, M.A.; Masett, R. 2018: Conservative surgery after neoadjuvant chemotherapy in patients with operable breast cancer Annali Italiani di Chirurgia 89: 290
Azria, D.; Ychou, M.; Senesse, P.; Dubois, J.B. 1999: Neoadjuvant treatment of operable esophageal cancers Gastroenterologie Clinique et Biologique 23(10): 1107-1108
Yabusaki, H.; Nashimoto, A.; Tanaka, O. 2003: Evaluation of TS-1 combined with cisplatin for neoadjuvant chemotherapy in patients with advanced gastric cancer Gan to Kagaku Ryoho. Cancer and ChemoTherapy 30(12): 1933-1940
Yonemura, Y.; Kinoshita, K.; Fujimura, T.; Fushida, S.; Sawa, T.; Matsuki, N.; Tanaka, S.; Kamata, T.; Takashima, T.; Miyazaki, I. 1996: Correlation of the histological effects and survival after neoadjuvant chemotherapy on gastric cancer patients Hepato-Gastroenterology 43(11): 1260-1272
Sun, B.; Song, S.-t.; Wu, S.-k.; Jiang, Z.-f.; Wang, T.; Zhang, S.-h.; Zhao, Y.-b.; Yu, C.-z.; Li, X.-b.; Yang, T.; Li, G.-j. 2009: Comparison of response evaluation methods of neoadjuvant chemotherapy in breast cancer patients Zhonghua Zhong Liu Za Zhi 31(10): 783-785
Su, J.; Chen, H.; Li, M.; Dong, J.; Lin, Z. 2015: Value of FOXP3 Tregs predicting the effectiveness of neoadjuvant chemotherapy in patients with breast cancer Zhonghua Yi Xue Za Zhi 95(8): 595-597